Showing results (271-280 of 343) with videos related to

Sort By:
Pageof 35
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord OvestC Cremolini, F Loupakis, C Antoniotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2012
The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasmsS Caponi, N Funel, A E Frampton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsC Cremolini, F Loupakis, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisC Cremolini, M Di Bartolomeo, A Amatu, et al.
The Pharmacogenomics Journal|December 24, 2008
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancerF Graziano, A Ruzzo, E Canestrari, et al.
The Pharmacogenomics Journal|February 12, 2014
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patientsF Loupakis, C Antoniotti, C Cremolini, et al.
British Journal of Cancer|July 16, 2009
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerF Loupakis, A Ruzzo, C Cremolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2003
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC)F Di Costanzo, A Sobrero, S Gasperoni, et al.
British Journal of Cancer|May 6, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resectionM Schirripa, F Bergamo, C Cremolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled studyE Van Cutsem, T Yoshino, H J Lenz, et al.
Pageof 35